These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15967567)

  • 21. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
    Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
    BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.
    Bunyavejchevin S
    J Med Assoc Thai; 2005 Nov; 88(11):1497-501. PubMed ID: 16471092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
    Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
    J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
    Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine].
    Dorschner W; Stolzenburg JU; Griebenow R; Halaska M; Brünjes R; Frank M; Wieners F
    Aktuelle Urol; 2003 Mar; 34(2):102-8. PubMed ID: 14566693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
    Jacquetin B; Wyndaele J
    Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):97-102. PubMed ID: 11516807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ; Kreder KJ; Pleil AM; Burgess SM; Reese PR
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S616-30. PubMed ID: 12516956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the success of drug treatment in urge urinary incontinence? What should be measured?
    Dede H; Dolen İ; Dede FS; Sivaslioglu AA
    Arch Gynecol Obstet; 2013 Mar; 287(3):511-8. PubMed ID: 23086134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Kaplan SA; Walmsley K; Te AE
    J Urol; 2005 Dec; 174(6):2273-5. discussion 2275-6. PubMed ID: 16280803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of tolterodine and patient compliance in pediatric patients with neurogenic detrusor overactivity.
    Christoph F; Moschkowitsch A; Kempkensteffen C; Schostak M; Miller K; Schrader M
    Urol Int; 2007; 79(1):55-9. PubMed ID: 17627170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.